Northwest Biotherapeutics (OTCMKTS:NWBO) Announces Quarterly Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) released its quarterly earnings results on Friday. The biotechnology company reported ($18.22) earnings per share (EPS) for the quarter, Zacks reports.

Northwest Biotherapeutics Trading Down 1.3%

OTCMKTS:NWBO opened at $0.24 on Friday. The firm has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.26. Northwest Biotherapeutics has a twelve month low of $0.17 and a twelve month high of $0.48. The company has a market capitalization of $369.04 million, a P/E ratio of -4.00 and a beta of -0.56.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.